Implementation of Tofersen Expanded Access Program (EAP) in the US, The Cumulative Experience of Six Academic Centers.

被引：0
|
作者：
Ajroud-Driss, Senda [1 ]
Babu, Suma [2 ]
Harms, Matthew [3 ]
Shneider, Neil [3 ]
Quinn, Colin [4 ]
Arcila-Londono, Ximena [5 ]
Bucelli, Robert [6 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL USA
[2] Harvard Med Sch, Dept Neurol, Boston, MA USA
[3] Columbia Univ, Dept Neurol, Vagelos Coll Physicians & Surg, New York, NY USA
[4] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA USA
[5] Henry Ford Hlth Detroit, Med Harry J Hoenselaar ALS Clin, Detroit, MI USA
[6] Washington Univ, Dept Neurol, Sch Med, St Louis, MO USA
来源：
MUSCLE & NERVE | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
126
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 26 条
  • [21] Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment
    Barros e Silva, Milton
    Schmerling, Rafael
    de Melo, Andreia Cristina
    Azevedo, Sergio
    Garicochea, Bernardo
    McWhirter, Elaine
    Smylie, Michael
    Gifoni, Markus
    dos Anjos, Carlos Henrique
    Petrella, Teresa
    Chacon, Matias
    Greco, Martin
    Nair, Suresh
    Avila, Alexandre
    Demelo, Sheena
    Jiang, Joel
    Ernst, Scott
    CANCER RESEARCH, 2017, 77
  • [22] Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
    Hultcrantz, Malin
    Anderson, Larry D., Jr.
    Anwer, Faiz
    Gasparetto, Cristina
    Kocoglu, Mehmet H.
    Lichtman, Eben I.
    Mo, Clifton
    Niesvizky, Ruben
    Lewis, Eric
    Li, Hong
    Paul, Sofia
    Petrone, Stephanie
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S440
  • [23] Clinical Experience With Efgartigimod in Generalized Myasthenia Gravis: Results From a Case Series of US-Based Patients Participating in an Expanded Access Program
    Khella, Sami
    Kuntz, Nancy
    Ostrovskiy, Denis
    Gelinas, Deborah
    Rahman, Omar
    Mahuwala, Zabeen
    NEUROLOGY, 2022, 99 (23) : S43 - S43
  • [24] Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a US expanded access program (EAP).
    Ochs, J
    Grous, JJ
    Warner, KL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [25] IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
    Girard, N.
    Valette, C. Audigier
    Cadranel, J.
    Monnet, I.
    Hureaux, J.
    Hilgers, W.
    Fauchon, E.
    Fabre, E.
    Besse, B.
    Brun, P.
    Coetmeur, D.
    Quoix, E.
    Mourlanette, P.
    Barlesi, F.
    Bordenave-Caffre, S.
    Egenod, T.
    Missy, P.
    Morin, F.
    Moro-Sibilot, D.
    Molinier, O.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Safety results of the US expanded access program (EAP) of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) for whom letrozole therapy is deemed appropriate
    Stearns, V.
    Smith, J. W., II
    Patel, R.
    Lu, D.
    Perkins, J. J.
    Cotter, M. J.
    Brufsky, A. M.
    CANCER RESEARCH, 2016, 76
123